ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 02/06/24

2024-02-06 07:25:47 ET More on Eli Lilly Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value Biotech And Pharma Diversification Pays Off Eli Lilly: The Cupboard Is Fully Stocked Eli Lilly beats top-line and bottom-line estimates; ...

Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors m...

2024-01-21 08:47:28 ET Summary Arrowhead Pharmaceuticals lacks focus with a pipeline of 16 programs, hindering its progress in bringing a product to market. The company has experienced setbacks, including poor data from ARO-AAT and the return of JNJ-3989 by Johnson & Johnson. ...

2024-01-06 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that on January 5, 2024, it closed the previously announced underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”). The offering was priced at $28.50 per sh...

2024-01-03 07:04:32 ET More on Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals: Transition To Commercialization Arrowhead Pharmaceuticals: Balance Sheet Concern Needs To Be Addressed Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2023 Earnings Call Transcript ...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten registered offering of 15,790,000 shares of its common stock, par value $0.001 per share (“Common Stock”), offered at a price of $28.50 per share, before underwriting discounts. The offerin...